The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Cannabidiol for the treatment of cannabis withdrawal syndrome: a case report: CBD and cannabis withdrawal
Open accessAbstract
WHAT IS KNOWN AND OBJECTIVE: Cannabis withdrawal in heavy users is commonly followed by increased anxiety, insomnia, loss of appetite, migraine, irritability, restlessness and other physical and psychological signs. Tolerance to cannabis and cannabis withdrawal symptoms are believed to be the result of the desensitization of CB1 receptors by THC. CASE SUMMARY: This report describes the case of a 19-year-old woman with cannabis withdrawal syndrome treated with cannabidiol (CBD) for 10 days. Daily symptom assessments demonstrated the absence of significant withdrawal, anxiety and dissociative symptoms during the treatment. WHAT IS NEW AND CONCLUSION: CBD can be effective for the treatment of cannabis withdrawal syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Based on findings from animal studies, we treated an inpatient with heavy cannabis dependence and episodes of cannabis withdrawal syndrome with CBD, which yielded positive results (143).”
From Translational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age (2018) · cites this paper as [143]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032
An inventory for measuring clinical anxiety: Psychometric properties.
Beck, A. T., Epstein, N., Brown, G., & Steer, R. A. (1988) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.56.6.893 · Cited by 14,407
Bisogno, T., Hanuš, L., PETROCELLIS, L. D., Tchilibon, S., Ponde, D. E., Brandi, I., Moriello, A. S., Davis, J. B., Mechoulam, R., & Marzo, V. D. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704327 · Cited by 1,315
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
Leweke, F. M., Piomelli, D., Pahlisch, F., Muhl, D., Gerth, C. W., Hoyer, C., Klosterkötter, J., Hellmich, M., & Koethe, D. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.15 · Cited by 1,059
Bergamaschi, M. M., Queiroz, R. H. C., Chagas, M. H. N., de Oliveira, D. C. G., De Martinis, B. S., Kapczinski, F., Quevedo, J., Roesler, R., Schröder, N., Nardi, A. E., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.6 · Cited by 771
Self-citationSafety and side effects of cannabidiol, a Cannabis sativa constituent
Machado Bergamaschi, M., Helena Costa Queiroz, R., Waldo Zuardi, A., & Alexandre S. Crippa, J. (2011) · Current Drug Safety · doi:10.2174/157488611798280924 · Cited by 558 · cited 1×
“CBD has proven to be a safe drug with no significant adverse effects in humans, even with chronic use(24) and in high doses.(12,25,26) Based on these findings, we investigated the effects of CBD in a subject with cannabis dependence and a history of cannabis withdrawal syndrome.”
BackgroundSelf-citationReview of the Validity and Significance of Cannabis Withdrawal Syndrome
Budney, A. J., Hughes, J. R., Moore, B. A., & Vandrey, R. G. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.11.1967 · Cited by 521
Cannabis and anxiety: a critical review of the evidence
Crippa, J. A., Zuardi, A. W., Martín‐Santos, R., Bhattacharyya, S., Atakan, Z., McGuire, P., & Fusar‐Poli, P. (2009) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.1048 · Cited by 509
Self-citationFusar-Poli, P., Crippa, J. A., Bhattacharyya, S., Borgwardt, S. J., Allen, P., Martin-Santos, R., Seal, M., Surguladze, S. A., O’Carrol, C., Atakan, Z., et al. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2008.519 · Cited by 465
Self-citationCannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action
Zuardi, A. W. (2008) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462008000300015 · Cited by 421 · cited 3×
“For instance, despite its low affinity for CB1 receptors, CBD is able to antagonize CB1R agonists at reasonably low concentrations.(12) Moreover, CBD can also inhibit the reuptake and hydrolysis of anandamide in animals(11) and in humans,(31) a mechanism that could be involved in the reduction of cannabis withdrawal s…”
BackgroundSelf-citation
Research works printed but not linked: 2
- Budney, 2010, [Pharmacological and psychosocial interventions for cannabis use disorders], Rev Bras Psiquiatr, 32, S46
- First, 1997, Structured clinical interview for DSM-IV axis I disorders - Clinican version (SCID-CV)
Cited by
Sorted by citations
Iffland, K., & Grotenhermen, F. (2017) · Cannabis & Cannabinoid Research · doi:10.1089/can.2016.0034 · Cited by 645
Cannabidiol Adverse Effects and Toxicity
Huestis, M. A., Solimini, R., Pichini, S., Pacifici, R., Carlier, J., & Busardò, F. P. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666190603171901 · Cited by 499
Freeman, T. P., & WINSTOCK, A. R. (2015) · Psychological Medicine · doi:10.1017/s0033291715001178 · Cited by 326
Translational investigation of the therapeutic potential of Cannabidiol (CBD): Toward a new age
Crippa, J. A., Guimarães, F. S., Campos, A. C., & Zuardi, A. W. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02009 · Cited by 308
Self-citationGarcía-Gutiérrez, M. S., Navarrete, F., Gasparyan, A., Austrich-Olivares, A., Sala, F., & Manzanares, J. (2020) · Biomolecules · doi:10.3390/biom10111575 · Cited by 306
Rosenberg, E. C., Tsien, R. W., Whalley, B. J., & Devinsky, O. (2015) · Neurotherapeutics · doi:10.1007/s13311-015-0375-5 · Cited by 292
Nabiximols as an Agonist Replacement Therapy During Cannabis Withdrawal: A Randomized Clinical Trial
Allsop, D. J., Copeland, J., Lintzeris, N., Dunlop, A. J., Montebello, M., Sadler, C., Rivas, G. R., Holland, R. M., Muhleisen, P., Norberg, M. M., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.3947 · Cited by 266
A systematic review of cannabidiol dosing in clinical populations
Millar, S., Stone, N. L., Bellman, Z. D., Yates, A. S., England, T. J., & O’Sullivan, S. E. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14038 · Cited by 261
The cannabis withdrawal syndrome: current insights
Bonnet, U., & Preuss, U. (2017) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s109576 · Cited by 221
Freeman, T. P., Hindocha, C., Baio, G., Shaban, N. D. C., Thomas, E. M., Astbury, D., Freeman, A. M., Lees, R., Craft, S., Morrison, P. D., et al. (2020) · The Lancet Psychiatry · doi:10.1016/s2215-0366(20)30290-x · Cited by 211
Cannabidiol (CBD) use in psychiatric disorders: A systematic review
Bonaccorso, S., Ricciardi, A., Zangani, C., Chiappini, S., & Schifano, F. (2019) · NeuroToxicology · doi:10.1016/j.neuro.2019.08.002 · Cited by 180
Cannabidiol reduces ethanol consumption, motivation and relapse in mice
Viudez‐Martínez, A., García‐Gutiérrez, M. S., Navarrón, C. M., Morales‐Calero, M. I., Navarrete, F., Torres‐Suárez, A. I., & Manzanares, J. (2017) · Addiction Biology · doi:10.1111/adb.12495 · Cited by 158
Englund, A., Freeman, T. P., Murray, R. M., & McGuire, P. K. (2017) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30075-5 · Cited by 156
Elsaid, S., Kloiber, S. M., & Foll, B. L. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.06.005 · Cited by 144
Cannabidiol as an Intervention for Addictive Behaviors: A Systematic Review of the Evidence
Prud'homme, M., Cata, R., & Jutras‐Aswad, D. (2015) · Substance Abuse Research and Treatment · doi:10.4137/sart.s25081 · Cited by 133
The Endocannabinoid System and Cannabidiol's Promise for the Treatment of Substance Use Disorder
Chye, Y., Christensen, E., Solowij, N., & Yücel, M. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00063 · Cited by 132
Trigo, J. M., Soliman, A., Quilty, L. C., Fischer, B., Rehm, J. T., Selby, P. L., Barnes, A. J., Huestis, M. A., George, T. P., Streiner, D. L., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0190768 · Cited by 123
Brents, L. K., & Prather, P. L. (2013) · Drug Metabolism Reviews · doi:10.3109/03602532.2013.839700 · Cited by 115
Greydanus, D. E., Hawver, E. K., Greydanus, M. M., & Merrick, J. (2013) · Frontiers in Public Health · doi:10.3389/fpubh.2013.00042 · Cited by 112
Nabiximols for the Treatment of Cannabis Dependence
Lintzeris, N., Bhardwaj, A. K., Mills, L., Dunlop, A. J., Copeland, J., McGregor, I. S., Bruno, R., Gugusheff, J., Phung, N., Montebello, M. E., et al. (2019) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.1993 · Cited by 111
The therapeutic role of Cannabidiol in mental health: a systematic review
Khan, R. A., Naveed, S., Mian, N., Fida, A., Raafey, M. A., & Aedma, K. K. (2020) · Journal of Cannabis Research · doi:10.1186/s42238-019-0012-y · Cited by 97
Mandolini, G. M., Lazzaretti, M., Pigoni, A., Oldani, L., Delvecchio, G., & Brambilla, P. (2018) · Epidemiology and Psychiatric Sciences · doi:10.1017/s2045796018000239 · Cited by 95
Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?
Zlebnik, N. E., & Cheer, J. F. (2016) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-070815-014038 · Cited by 82
Batalla, A., Janssen, H., Gangadin, S. S., & Bossong, M. G. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8071058 · Cited by 79
Role of Cannabidiol in the Therapeutic Intervention for Substance Use Disorders
Navarrete, F., García‐Gutiérrez, M. S., Gasparyan, A., Austrich-Olivares, A., & Manzanares, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.626010 · Cited by 81
Review: Cannabinoids as Medicinals
Khalsa, J. H., Bunt, G. C., Blum, K., Maggirwar, S. B., Galanter, M. S., & Potenza, M. N. (2022) · Current Addiction Reports · doi:10.1007/s40429-022-00438-3 · Cited by 72
Cannabidiol for the treatment of crack-cocaine craving: an exploratory double-blind study
de Meneses-Gaya, C., Crippa, J. A. S., Hallak, J. E. C., Miguel, A. C., Laranjeira, R., Bressan, R. A., Zuardi, A. W., & Lacerda, A. L. T. (2020) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2020-1416 · Cited by 59
Self-citationProgress toward pharmacotherapies for cannabis-use disorder: an evidence-based review
Copeland, J., & Pokorski, I. (2016) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s89857 · Cited by 59
The therapeutic potential of purified cannabidiol
O’Sullivan, S. E., Jensen, S. S., Nikolajsen, G. N., Bruun, H. Z., Bhuller, R., & Hoeng, J. (2023) · Journal of Cannabis Research · doi:10.1186/s42238-023-00186-9 · Cited by 61
Cannabidiol Oil for Decreasing Addictive Use of Marijuana: A Case Report.
Shannon, S. M., & Opila-Lehman, J. (2015) · PubMed Central · Cited by 56
Novel Pharmacologic Approaches to Treating Cannabis Use Disorder
Balter, R. E., Cooper, Z. D., & Haney, M. (2014) · Current Addiction Reports · doi:10.1007/s40429-014-0011-1 · Cited by 54
Cannabidiol in the context of substance use disorder treatment: A systematic review
Paulus, V., Billieux, J., Benyamina, A., & Karila, L. (2022) · Addictive Behaviors · doi:10.1016/j.addbeh.2022.107360 · Cited by 52
THC and CBD: Villain versus Hero? Insights into Adolescent Exposure
Pintori, N., Caria, F., Luca, M. A. D., & Miliano, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065251 · Cited by 50
Is there a role for cannabidiol in psychiatry?
Khoury, J. M., das Neves, M. D. C. L., Roque, M. A. V., Queiroz, D. A. D. B., de Freitas, A. A. C., de Fátima, Â., Moreira, F. A., & Garcia, F. D. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1285049 · Cited by 45
Cannabidiol and substance use disorder: Dream or reality
Karimi‐Haghighi, S., Razavi, Y., Iezzi, D., Scheyer, A. F., Manzoni, O. J., & Haghparast, A. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.108948 · Cited by 46
Effects of cannabidiol on alcohol-related outcomes: A review of preclinical and human research.
Nona, C. N., Hendershot, C. S., & Foll, B. L. (2019) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000272 · Cited by 41
Fischer, B., Kuganesan, S., Gallassi, A. D., Malcher‐Lopes, R., van den Brink, W., & Wood, E. (2015) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2015.09.005 · Cited by 41
Navarrete, F., Aracil-Fernández, A., & Manzanares, J. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14226 · Cited by 38
Anooshe, M., Nouri, K., Karimi‐Haghighi, S., Mousavi, Z., & Haghparast, A. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113158 · Cited by 40
Alviz-Amador, A., Contreras‐Puentes, N., & Mercado‐Camargo, J. (2021) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2021.107590 · Cited by 39
Narayan, A. J., Downey, L. A., Manning, B., & Hayley, A. C. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104941 · Cited by 36
Pinto, J. V., Saraf, G., Frysch, C., Vigo, D., Keramatian, K., Chakrabarty, T., Lam, R. W. M., Kauer‐Sant’Anna, M., & Yatham, L. N. (2019) · The Canadian Journal of Psychiatry · doi:10.1177/0706743719895195 · Cited by 38
Cannabis use, harms and the management of cannabis use disorder
Copeland, J., Clement, N., & Swift, W. (2014) · Neuropsychiatry · doi:10.2217/npy.13.90 · Cited by 33
Frequent cannabis users demonstrate low knowledge of cannabinoid content and dosages
Kruger, D. J., Kruger, J. S., & Collins, R. L. (2020) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2020.1752150 · Cited by 31
Kibret, B. G., Canseco-Alba, A., Onaivi, E. S., & Engidawork, E. (2023) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2023.1137957 · Cited by 30
Vallée, A., Lecarpentier, Y., & Vallée, J.-N. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01086-1 · Cited by 23
Cannabidiol and its Potential Evidence-Based Psychiatric Benefits – A Critical Review
Dammann, I., Rohleder, C., & Leweke, F. M. (2024) · Pharmacopsychiatry · doi:10.1055/a-2228-6118 · Cited by 24
Alegre-Zurano, L., Berbegal-Sáez, P., Luján, M. Á., Cantacorps, L., Martín‐Sánchez, A., García-Baos, A., & Valverde, O. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112708 · Cited by 15
Harm to Others from Substance Use and Abuse: The Underused Potential in Nationwide Registers
Lund, I. O., & Bukten, A. (2015) · Substance Abuse Research and Treatment · doi:10.4137/sart.s23545 · Cited by 18
Tijani, A. O., Garg, J., Frempong, D., Verana, G., Kaur, J., Joga, R., Sabanis, C. D., Kumar, S., Kumar, N., & Puri, A. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.06.034 · Cited by 18
Pacheco, J. C., Souza, J. D. S., Hallak, J. E. C., Osório, F. D. L., Campos, A. C., Guimarães, F. S., Zuardi, A. W., & Crippa, J. A. S. (2021) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001405 · Cited by 16
Self-citationAnxiety Modulation by Cannabinoids—The Role of Stress Responses and Coping
Haller, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115777 · Cited by 17
Cannabinoid concentrations in Canada's regulated medical cannabis industry
Mammen, G., de Freitas, L., Rehm, J. T., & Rueda, S. (2017) · Addiction · doi:10.1111/add.13738 · Cited by 16
Basavarajappa, B. S., & Subbanna, S. (2024) · Biomolecules · doi:10.3390/biom14101296 · Cited by 14
Liu, L., Li, J., Wang, C., Xu, Y., Leung, C., Yang, G., Lin, S., Zhang, S., Tan, Y., Zhang, H., et al. (2022) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2022.2073450 · Cited by 12
Cannabidiol and 5-HT1A Receptors
Fogaça, M. V., Campos, A. C., & Guimarães, F. S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800213-1.00070-5 · Cited by 11
Bhardwaj, A. K., Mills, L., Doyle, M., Sahid, A., Montebello, M., Monds, L., Arunogiri, S., Haber, P., Lorenzetti, V., Lubman, D. I., et al. (2024) · BMC Psychiatry · doi:10.1186/s12888-024-05616-3 · Cited by 10
Dyck, G. J. B., Maayah, Z. H., Eurich, D. T., & Dyck, J. R. B. (2021) · Schizophrenia Bulletin Open · doi:10.1093/schizbullopen/sgab053 · Cited by 9
Cannabidiol in the Management of In-Patient Cannabis Withdrawal: Clinical Case Series
Pokorski, I., Clement, N., Phung, N., Weltman, M., Fu, S., & Copeland, J. (2017) · Future Neurology · doi:10.2217/fnl-2016-0035 · Cited by 9
Souza, A. J., Guimarães, F. S., & Gomes, F. V. (2023) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114504 · Cited by 8
Cyclic Vomiting Syndrome and Cannabis Hyperemesis Syndrome
Lathrop, J. R., Rosen, S. N., Heitkemper, M. M., & Buchanan, D. T. (2023) · Gastroenterology Nursing · doi:10.1097/sga.0000000000000730 · Cited by 6
Cannabinoids for Substance Use Disorder Treatment: What Does the Current Evidence Say?
Fernandes, J. A. B., Filev, R., & Fidalgo, T. M. (2023) · Cannabis and Cannabinoid Research · doi:10.1089/can.2023.0065 · Cited by 6
Cannabidiol for the Treatment of Drug Use Disorders
SANTOS, R. G. D., Hallak, J. E. C., Zuardi, A. W., & Crippa, J. A. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-800756-3.00113-7 · Cited by 5
Self-citationOliver, D., Englund, A., Chesney, E., Chester, L. A., Wilson, J., Sovi, S., Wigroth, S., Hodsoll, J. P., Strang, J., Murray, R. M., et al. (2023) · Addiction · doi:10.1111/add.16353 · Cited by 5
Treatment of Cannabis Use Disorders
Ramesh, D., & Haney, M. (2014) · Springer eBooks · doi:10.1007/978-88-470-5322-9_14 · Cited by 5
Overview of Current State-of-the-Art Treatments for Cannabis Use Disorders, and Future Directions
Copeland, J., Pokorski, I., & Gibson, L. (2017) · Current Addiction Reports · doi:10.1007/s40429-017-0151-1 · Cited by 5
Cogan, P. S. (2020) · Journal of Dietary Supplements · doi:10.1080/19390211.2020.1769246 · Cited by 5
Cannabidiol as a candidate pharmacotherapy for sleep disturbance in alcohol use disorder
Gendy, M. N. S., Frey, B. N., Ameringen, M. V., Kuhathasan, N., & MacKillop, J. M. (2023) · Alcohol and Alcoholism · doi:10.1093/alcalc/agad031 · Cited by 5
Evaluation of anxiety-like behaviors following ethanol withdrawal in mice: effects of cannabidiol
Coltri, L. P., Bonassoli, V. T., Milani, H., & de Oliveira, R. M. W. (2020) · Acta Scientiarum Health Sciences · doi:10.4025/actascihealthsci.v42i1.53001 · Cited by 3
A nutraceutical role for cannabidiol. Why not?
Pierro, F. D. (2015) · Nutrafoods · doi:10.1007/s13749-015-0037-6 · Cited by 3
Cannabinoids for the treatment of cannabis abuse disorder
Rodríguez, A., & Zavala, C. (2018) · Medwave · doi:10.5867/medwave.2018.06.7286 · Cited by 3
Canabidiol e suas indicações em psiquiatría
Ramírez, J. F. M. (2021) · Revista Digital Palabra (Universidad Pontificia Bolivariana) · doi:10.18566/medupb.v40n1.a09 · Cited by 3
Briânis, R. C., Moreira, F. A., & Iglesias, L. P. (2024) · International review of neurobiology · doi:10.1016/bs.irn.2024.03.006 · Cited by 2
Cannabidiol in the Treatment of Mood Disorders
Pinto, J. V., Ziak, M. L., Schaffer, A., & Yatham, L. N. (2022) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-022-00265-3 · Cited by 3
Cannabinoids and drug addiction
Luca, M. A. D., & Fattore, L. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417041-4.00012-6 · Cited by 2
Cannabidiol and Cannabis Use Disorder
García‐Gutiérrez, M. S., Navarrete, F., Viudez‐Martínez, A., Gasparyan, A., Caparrós, E., & Manzanares, J. (2018) · Springer eBooks · doi:10.1007/978-3-319-90365-1_5 · Cited by 2
The good face of Cannabis sativa: Cannabidiol
Evren, C. (2019) · Dusunen Adam The Journal of Psychiatry and Neurological Sciences · doi:10.14744/dajpns.2019.00041 · Cited by 2
Legalisation and Liberalisation of Cannabis: The Benefits and Drawbacks of the Global Trend
Fasesan, O. (2022) · Annals of Health Research (The Journal of the Medical and Dental Consultants Association of Nigeria OOUTH Sagamu Nigeria) · doi:10.30442/ahr.0803-01-168 · Cited by 1
Cannabinoid for alcohol use disorder
Marquez, J. D., Dezanetti, T., Walz, R., & de Carvalho, C. R. (2024) · International review of neurobiology · doi:10.1016/bs.irn.2024.08.005 · Cited by 1
Ross, J. A., Riccardelli, W., Robitaille, J., & Levy, S. (2025) · Adolescents · doi:10.3390/adolescents5040054 · Cited by 1
Pasic, J. (2017) · Springer eBooks · doi:10.1007/978-3-319-58260-3_42 · Cited by 1
Spelta, L. E. W., Real, C. C., Bruno, V., Buchpiguel, C. A., Garcia, R. C. T., Torres, L. H., Faria, D. D. P., & Marcourakis, T. (2024) · Journal of Neuroscience Research · doi:10.1002/jnr.25327 · Cited by 1
THERAPEUTIC POTENTIAL OF CANNABIDIOL: THE MOST IMPORTANT ACHIEVEMENTS ON THE WAY TO A NEW ERA
Shevchuk, M. M., & Volos, L. I. (2023) · Medical Science of Ukraine (MSU) · doi:10.32345/2664-4738.2.2023.17 · Cited by 5
Cannabidiol effects on cocaine-seeking behaviour and incubation of craving in micePreprint
Alegre-Zurano, L., Luján, M. Á., Cantacorps, L., Martín‐Sánchez, A., García-Baos, A., & Valverde, O. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.18.423391 · Cited by 1
Karl, T., & Arnold, J. C. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107360556.026
With pot now legal, therapies sought to blunt high of marijuana
Owens, B. (2014) · Nature Medicine · doi:10.1038/nm0214-107
Pan, J. (2016) · TSpace (University of Toronto)
Ferreira, J. V., Correa, L. C., da Costa, D. C., & Hage-Melim, L. I. D. S. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.82184
Cannabidiol-mediated regulation of spontaneous cannabinoid withdrawal
Navarrete, F., Aracil-Fernández, A., Gasparyan, A., & Manzanares, J. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.11.727
The use of cannabidiol in addiction therapy in the light of clinical trials.
Lewandowska, J. A., Kapała, J. M., & Puchała, Ł. (2020) · Farmacja Polska · doi:10.32383/farmpol/127827
Substance dependence and abuse
Pietropaolo, S., Sluyter, F., & Crusio, W. E. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107360556.024
Cannabis de grado médico para el tratamiento de la dependencia a Δ-9-Tetrahidrocannabinol
Pavlovsky, F., Groisman, R., Hurtado, A. K., & García, L. (2022) · Vertex Revista Argentina de Psiquiatría · doi:10.53680/vertex.v33i157.265
Wolinsky, D. I., & Vandrey, R. G. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-89862-1.00037-4
Scarante, F. F. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.17.2023.tde-29062023-112405
MICROSCOPIC ARCHITECTURE OF THE LIVER OF EXPERIMENTAL RATS AFTER CANNABIDIOL OIL APPLICATIONS
Shevchuk, M. M., & Volos, L. I. (2023) · Polonia University Scientific Journal · doi:10.23856/5845
Rabbani, A. J., & Rabbani, R. R. (2020) · Journal of Emerging Investigators · doi:10.59720/20-062
Cannabidiol for Treatment of Child and Adolescent Psychiatric Disorders
Melnyk, C., & Wagner, K. D. (2024) · Psychiatric annals · doi:10.3928/00485713-20240320-01
Substance Use Disorders and the Endocannabinoid System: A New Narrative
García‐Gutiérrez, M. S., Torregrosa, A. B., Rueda, F. N., Gasparyan, A., Esteve, L. G., Navarro, D., & Manzanares, J. (2024) · Springer eBooks · doi:10.1007/978-3-031-32035-4_140-1
Substance Use Disorders and the Endocannabinoid System: A New Narrative
García‐Gutiérrez, M. S., Torregrosa, A. B., Rueda, F. N., Gasparyan, A., Esteve, L. G., Navarro, D., & Manzanares, J. (2025) · Springer eBooks · doi:10.1007/978-3-031-73368-0_140 · Cited by 1
de Pontes, L. R., & Ribeiro, S. T. G. (2025) · Progress in brain research · doi:10.1016/bs.pbr.2025.08.001
Metadata
- Authors
- Crippa, J. A. S., Hallak, J. E. C., Machado-de-Sousa, J. P., Queiroz, R. H. C., Bergamaschi, M., Chagas, M. H. N., & Zuardi, A. W.
- Affiliations
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (BR)
- Universidade de São Paulo (BR)
- Venue
- Journal of Clinical Pharmacy and Therapeutics
- Publisher
- Hindawi Limited
- Published
- 2012-10-24
- Volume
- 38
- Issue
- 2
- Pages
- 162-164
- ISSN
- 0269-4727 (ISSN-L)
- OpenAlex
- W1889449076
- Cited by
- 101
- References
- 33
- Citations by year
- 2025: 3 · 2024: 9 · 2023: 13 · 2022: 10 · 2021: 7 · 2020: 10 · 2019: 12 · 2018: 6 · 2017: 10 · 2016: 4 · 2015: 8 · 2014: 7 · 2013: 2
- FWCI
- 3.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Clinical Pharmacy and Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cannabis and Cannabinoid Research
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
- Keywords
- cannabidiol, cannabis withdrawal syndrome, anxiety, dissociative symptoms, insomnia, cannabis use disorder
- MeSH terms
- Adult, Cannabidiol, Cannabis, Female, Humans, Substance Withdrawal Syndrome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
